SAB Biotherapeutics
SABS
25 hedge funds and large institutions have $3.37M invested in SAB Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
13% more capital invested
Capital invested by funds: $2.99M → $3.37M (+$375K)
3.23% less ownership
Funds ownership: 23.94% → 20.71% (-3.2%)
4% less funds holding
Funds holding: 26 → 25 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$28.3K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$19.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.04K |
| 5 |
Renaissance Technologies
New York
|
+$1.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
-$358K |
| 2 |
SOS
Silver Oak Securities
Jackson,
Tennessee
|
-$29.9K |
| 3 |
BlackRock
New York
|
-$25.3K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.3K |
| 5 |
Millennium Management
New York
|
-$22.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HWM
26
HB Wealth Management
Atlanta,
Georgia
| – | -$358K | -263,200 | Closed |
|
|
SOS
27
Silver Oak Securities
Jackson,
Tennessee
| – | -$29.9K | -20,188 | Closed |
|
|
XT
28
XTX Topco
George Town,
Cayman Islands
| – | -$22.3K | -16,555 | Closed |
|
|
29
Millennium Management
New York
| – | -$22.1K | -16,351 | Closed |
|
SABS Hedge Fund Activity: Q2 2025 in Review
25 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q2 2025, worth a combined $3.37M — up 13% from $2.99M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of SABS and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $28.3K. The largest seller was HB Wealth Management, exiting entirely with an estimated $358K sold.
- 25 institutional investors held SAB Biotherapeutics (SABS) as of Q2 2025, down from 26 in Q1 2025.
- Funds reported $3.37M of SAB Biotherapeutics stock for Q2 2025, up 13% quarter-over-quarter.
- 3 funds opened new SAB Biotherapeutics positions in Q2 2025 and 4 closed out, a net change of -1 holder.
- The largest SAB Biotherapeutics buyer in Q2 2025 was Citadel Advisors, an estimated $28.3K added.
- The largest SAB Biotherapeutics seller in Q2 2025 was HB Wealth Management, an estimated $358K sold.
Based on aggregated 13F filings for Q2 2025.